(MFC) Manulife Financial - Ratings and Ratios
Insurance, Annuities, Wealth, Asset Management, Banking
MFC EPS (Earnings per Share)
MFC Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 22.0% |
| Value at Risk 5%th | 34.8% |
| Reward | |
|---|---|
| Sharpe Ratio | 0.25 |
| Alpha | -5.88 |
| Character | |
|---|---|
| Hurst Exponent | 0.366 |
| Beta | 1.021 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.75% |
| Mean DD | 3.76% |
Description: MFC Manulife Financial September 26, 2025
Manulife Financial Corp (NYSE:MFC) operates globally through three primary segments: Wealth & Asset Management, Insurance & Annuity Products, and Corporate & Other. The Wealth & Asset Management arm delivers investment advice and retirement solutions to retail, institutional, and pension-plan clients via agents, broker-dealers, financial advisors, and bank partners. The Insurance & Annuity Products segment sells life, long-term care, and annuity policies, as well as deposit and credit products, through a mix of agents, brokers, banks, and direct-to-consumer channels. The Corporate & Other segment includes property-and-casualty reinsurance, run-off operations, timberland and agricultural investments, and ancillary services such as brokerage, fund management, and integrated banking.
Key financial indicators from the most recent annual report (2023) show a net income of roughly US $7.4 billion, a return on equity (ROE) of 13 % and a dividend yield near 6.5 %, placing Manulife among the higher-yielding insurers in North America. The company’s capital adequacy ratios-Core Tier 1 at 13.5 % and Total Capital at 19 %-exceed the minimum requirements set by Canadian regulators, providing a buffer against underwriting volatility.
From a macro-economic perspective, Manulife’s earnings are sensitive to interest-rate movements because longer-duration life-insurance liabilities are marked to market; a 100-basis-point rise in rates historically lifts its net interest margin by about 0.8 % (based on a 2022-2023 internal sensitivity analysis). Additionally, the firm’s exposure to the U.S. market-accounting for roughly 45 % of total premiums-means that U.S. mortality trends and healthcare cost inflation are material drivers of future underwriting profitability. In the Asian segment, growth in middle-class wealth is a leading catalyst, but it also introduces currency risk; the 2024 forward FX outlook suggests a potential 2-3 % depreciation of the Canadian dollar relative to the yuan, which could erode reported earnings if not hedged.
For a deeper, data-driven dive into how these drivers translate into valuation metrics, you might explore the analyst dashboards on ValueRay, where scenario-based models can help quantify the impact of interest-rate shifts and currency movements on Manulife’s projected cash flows.
MFC Stock Overview
| Market Cap in USD | 54,850m |
| Sub-Industry | Life & Health Insurance |
| IPO / Inception | 1999-09-23 |
| Return 12m vs S&P 500 | -6.84% |
| Analyst Rating | 3.77 of 5 |
MFC Dividends
| Dividend Yield | 3.67% |
| Yield on Cost 5y | 9.95% |
| Yield CAGR 5y | 1.19% |
| Payout Consistency | 95.2% |
| Payout Ratio | 55.0% |
MFC Growth Ratios
| CAGR | 30.40% |
| CAGR/Max DD Calmar Ratio | 1.81 |
| CAGR/Mean DD Pain Ratio | 8.08 |
| Current Volume | 3516k |
| Average Volume | 1338.2k |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (6.05b TTM) > 0 and > 6% of Revenue (6% = 2.41b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 0.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 63.28% (prev 241.4%; Δ -178.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 28.61b > Net Income 6.05b (YES >=105%, WARN >=100%) |
| Net Debt (-10.50b) to EBITDA (7.12b) ratio: -1.47 <= 3.0 (WARN <= 3.5) |
| Current Ratio 72.04 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.72b) change vs 12m ago -4.67% (target <= -2.0% for YES) |
| Gross Margin 41.63% (prev 93.18%; Δ -51.55pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 4.25% (prev 4.72%; Δ -0.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.49 (EBITDA TTM 7.12b / Interest Expense TTM 1.57b) >= 6 (WARN >= 3) |
Altman Z'' 0.29
| (A) 0.03 = (Total Current Assets 25.79b - Total Current Liabilities 358.0m) / Total Assets 977.47b |
| (B) 0.00 = Retained Earnings (Balance) 4.54b / Total Assets 977.47b |
| (C) 0.01 = EBIT TTM 8.60b / Avg Total Assets 946.37b |
| (D) 0.05 = Book Value of Equity 42.22b / Total Liabilities 926.22b |
| Total Rating: 0.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.48
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield 43.04% = 5.0 |
| 3. FCF Margin 71.18% = 7.50 |
| 4. Debt/Equity 0.27 = 2.47 |
| 5. Debt/Ebitda -1.47 = 2.50 |
| 6. ROIC - WACC (= 3.97)% = 4.96 |
| 7. RoE 11.91% = 0.99 |
| 8. Rev. Trend -18.41% = -1.38 |
| 9. EPS Trend -21.18% = -1.06 |
What is the price of MFC shares?
Over the past week, the price has changed by +1.18%, over one month by +5.39%, over three months by +12.92% and over the past year by +7.31%.
Is Manulife Financial a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MFC is around 37.33 USD . This means that MFC is currently undervalued and has a potential upside of +11.73% (Margin of Safety).
Is MFC a buy, sell or hold?
- Strong Buy: 3
- Buy: 5
- Hold: 4
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the MFC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.8 | -16.8% |
| Analysts Target Price | 27.8 | -16.8% |
| ValueRay Target Price | 41.7 | 24.8% |
MFC Fundamental Data Overview November 04, 2025
P/E Trailing = 14.5811
P/E Forward = 10.101
P/S = 1.755
P/B = 1.7158
P/EG = 0.7746
Beta = 1.021
Revenue TTM = 40.19b CAD
EBIT TTM = 8.60b CAD
EBITDA TTM = 7.12b CAD
Long Term Debt = 13.28b CAD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 13.28b CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -10.50b CAD (from netDebt column, last quarter)
Enterprise Value = 66.47b CAD (76.97b + Debt 13.28b - CCE 23.77b)
Interest Coverage Ratio = 5.49 (Ebit TTM 8.60b / Interest Expense TTM 1.57b)
FCF Yield = 43.04% (FCF TTM 28.61b / Enterprise Value 66.47b)
FCF Margin = 71.18% (FCF TTM 28.61b / Revenue TTM 40.19b)
Net Margin = 15.06% (Net Income TTM 6.05b / Revenue TTM 40.19b)
Gross Margin = 41.63% ((Revenue TTM 40.19b - Cost of Revenue TTM 23.46b) / Revenue TTM)
Gross Margin QoQ = 26.74% (prev 91.41%)
Tobins Q-Ratio = 0.07 (Enterprise Value 66.47b / Total Assets 977.47b)
Interest Expense / Debt = 2.70% (Interest Expense 358.0m / Debt 13.28b)
Taxrate = 14.95% (338.0m / 2.26b)
NOPAT = 7.32b (EBIT 8.60b * (1 - 14.95%))
Current Ratio = 72.04 (Total Current Assets 25.79b / Total Current Liabilities 358.0m)
Debt / Equity = 0.27 (Debt 13.28b / totalStockholderEquity, last quarter 49.85b)
Debt / EBITDA = -1.47 (Net Debt -10.50b / EBITDA 7.12b)
Debt / FCF = -0.37 (Net Debt -10.50b / FCF TTM 28.61b)
Total Stockholder Equity = 50.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.62% (Net Income 6.05b / Total Assets 977.47b)
RoE = 11.91% (Net Income TTM 6.05b / Total Stockholder Equity 50.81b)
RoCE = 13.42% (EBIT 8.60b / Capital Employed (Equity 50.81b + L.T.Debt 13.28b))
RoIC = 12.65% (NOPAT 7.32b / Invested Capital 57.86b)
WACC = 8.68% (E(76.97b)/V(90.24b) * Re(9.78%) + D(13.28b)/V(90.24b) * Rd(2.70%) * (1-Tc(0.15)))
Discount Rate = 9.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -4.49%
[DCF Debug] Terminal Value 75.13% ; FCFE base≈26.57b ; Y1≈31.13b ; Y5≈47.15b
Fair Price DCF = 353.8 (DCF Value 597.88b / Shares Outstanding 1.69b; 5y FCF grow 18.26% → 3.0% )
EPS Correlation: -21.18 | EPS CAGR: 13.54% | SUE: -0.19 | # QB: 0
Revenue Correlation: -18.41 | Revenue CAGR: 30.92% | SUE: 1.24 | # QB: 1
Additional Sources for MFC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle